COVID-19 Vaccine Moderna National Protocol

Reference no:	COVID-19 Vaccine Moderna Protocol
Version no:	v3.4
Valid from:	29 March 2022
Review date:	01 March 2023
Expiry date:	31 March 2023

1. About the National Protocol

This protocol is for the supply and administration of COVID-19 Vaccine Moderna to individuals in accordance with the national COVID-19 vaccination programme. This protocol only allows administration during or in anticipation of COVID-19 pandemic where the disease represents a serious risk or potentially serious risk to human health.

This protocol is for the supply and administration of COVID-19 Vaccine Moderna by appropriately trained persons in accordance with regulation 247A of the Human Medicines Regulation 2012, as inserted by The Human Medicines (Coronavirus and Influenza) (Amendment) Regulations 2020

The Scottish Government has developed this protocol which has been approved by the Scottish Ministers to facilitate the delivery of the national COVID-19 vaccination programme by Health Boards in Scotland and any organisation a Health Board makes arrangements with to deliver such VHUYLFHV RQ LWV EHKDOI U.HIHUUHG Please note that in the FRQWH[W RI WKLV SURWRF: RO ³WKH SURYLG

(a) a Health Board,
(b) a Health Board working with Armed Forces staff where Armed Forces staff are working in Health Board settings, or
(c) an organisation delivering services on behalf of a Health Board.

This protocol may be followed wholly from patient assessment through to post-vaccination by a single person. Alternatively, obtaining consent and patient assessment may be undertaken by a registered healthcare professional with the process of administration undertaken by a non-registered professional or a non-registered Armed Forces staff member under clinical supervision.

Where multiple person models are used the provider must ensure that all elements of the protocol are complied with in the provision of vaccination to each patient.

The provider is responsible for ensuring that persons are trained and competent to safely deliver the activity they are authorised to provide under this protocol. As a minimum, competence requirements stipulated in the protocol und HU µ&KDUWHU RI VWDII¶ PXVW EH DGKHUHG WR

Category	Description
	symptoms commonly reported by vaccine recipients in the clinical trials. Generally, these symptoms were found to resolve within one to two days without treatment but paracetamol can be taken if necessary to relieve any of these symptoms. x Inform the individual/carer that anyone who has any of the following symptoms after vaccination should seek medical advice urgently: ¾ chest pain ¾ shortness of breath ¾ feelings of having a fast-beating, fluttering, or pounding heart x As has always been recommended, any fever after vaccination should be monitored and if individuals are concerned about their health at any time, they should seek advice from their GP or NHS24 x The individual should be advised to seek medical advice in the event of a severe adverse reaction. x Inform the individual that they can report suspected adverse reactions to the MHRA using the Yellow Card reporting scheme on: http://yellowcard.mhra.gov.uk. x Immunosuppressed individuals should be advised that they may not make a full immune response to the vaccine and they should continue to take appropriate measures to protect themselves against this infection. x When administration is postponed advise the individual how future vaccination may be accessed x When applicable, advise the individual/carer when to return for vaccination or when a subsequent vaccine dose is due.
Observation following vaccination	Following COVID-19 vaccine administration, individuals should be observed for any immediate reactions whilst they are receiving any verbal post vaccination information and exiting the centre.